Effectiveness and safety of first-generation protease inhibitors in clinical practice: Hepatitis C virus patients with advanced fibrosis

doi:10.3748/wjg.v21.i30.9163

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 21, Issue 30

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (4007)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-3) series, Tables (1-5) series.

Item

Count

PDF

400

WORD

291

HTML

2957

Figures (1-3)

172

Tables (1-5)

187

Sum=4007

Aug 14, 2015 (publication date) through Aug 24, 2024

Times Cited of This Article

Times Cited (9)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Prospective Study

World J Gastroenterol. Aug 14, 2015; 21(30): 9163-9174
Published online Aug 14, 2015. doi: 10.3748/wjg.v21.i30.9163

Table 4 Stop treatment modified-intention-to-treatment group n (%)

	All patients (n = 952)							TN (n = 298)			TE (n = 654)
	All patients (n = 952)	TN (n = 298)	TE (n = 654)	P value	BOC (n = 321)	TVR (n = 631)	P value	BOC (n = 112)	TVR (n = 186)	P value	BOC (n = 209)	TVR (n = 445)	P value
Stop treatment	263/952 (28)	97/298 (33)	166/654 (25)	0.022	88/321 (27)	175/631 (28)	NS	33/112 (30)	64/186 (34)	NS	55/209 (26)	111/445 (25)	NS
Non-VR	133/263 (51)	39/97 (40)	94/166 (57)	0.010	48/88 (54)	85/175 (49)	NS	11/33 (33)	28/64 (44)	NS	37/55 (67)	54/111 (51)	NS
Severe AE	83/263 (31)	31/97 (32)	52/166 (31)	NS	22/88 (25)	61/175 (35)	NS	10/33 (30)	21/64 (33)	NS	12/55 (22)	40/111 (36)	NS
Abandonment	6/263 (2)	2/97 (2)	4/166 (2)	NS	4/88 (4)	2/175 (1)	NS	2/33 (6)	0/64 (0)	NS	2/55 (4)	2/111 (2)	NS
Infection	6/263 (2)	2/97 (2)	4/166 (2)	NS	4/88 (4)	2/175 (1)	NS	2/33 (6)	0/64 (0)	NS	2/55 (4)	2/111 (2)	NS
Exitus	11/263 (4)	8/97 (8)	3/166 (2)	0.020	3/88 (3)	8/175 (5)	NS	2/33 (6)	6/64 (9)	NS	1/55 (2)	2/111 (2)	NS
Other	14/263 (5)	5/97 (5)	9/166 (5)	NS	3/88 (3)	11/175 (6)	NS	2/33 (6)	3/64 (5)	NS	1/55 (2)	8/111 (7)	NS

Bivariate analysis: χ² tests. NS: Not significant; BOC: Boceprevir; TVR: Telaprevir; Non-VR: Non-virologic response; AE: Adverse effect; TN: Treatment-naïve patients; TE: Treatment-experienced patients.

Citation: Salmerón J, Vinaixa C, Berenguer R, Pascasio JM, Sánchez Ruano JJ, Serra M&, Gila A, Diago M, Romero-Gómez M, Navarro JM, Testillano M, Fernández C, Espinosa D, Carmona I, Pons JA, Jorquera F, Rodriguez FJ, Pérez R, Montero JL, Granados R, Fernández M, Martín AB, Muñoz de Rueda P, Quiles R, Alhambra Spanish Study Group. Effectiveness and safety of first-generation protease inhibitors in clinical practice: Hepatitis C virus patients with advanced fibrosis. World J Gastroenterol 2015; 21(30): 9163-9174
URL: https://www.wjgnet.com/1007-9327/full/v21/i30/9163.htm
DOI: https://dx.doi.org/10.3748/wjg.v21.i30.9163